[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343032-105":59,"doc-detail-343032-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","stratification-to-neoadjuvant-radiotherapy-in-rectal-cancer-by-regimen-and-transcriptional-signatures","Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures","","Response to neoadjuvant radiotherapy (RT) in rectal cancer links to immune and stromal transcriptional signatures, yet their performance across different chemoradiotherapy regimens, within individual consensus molecular subtypes (CMS), and their survival impact are unclear. Gene expression and pretreatment biopsy data from nine primary rectal tumor cohorts (N=826) were integrated to test transcriptomic signatures for pathologic complete response (pCR), considering regimen or CMS. Immune and stromal signatures associated with pCR and non-pCR, respectively, with radiosensitivity showing the strongest effect. Oxaliplatin changed stromal direction and improved pCR odds; cytotoxic lymphocytes predicted pCR only in CMS1 and CMS4. Survival associations were limited to pCR and radiosensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stratification-to-neoadjuvant-radiotherapy-in-rectal-cancer-by-regimen-and-transcriptional-signatures/343032/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stratification-to-neoadjuvant-radiotherapy-in-rectal-cancer-by-regimen-and-transcriptional-signatures/343032.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were transcriptional signatures and clinical data combined in the study?","Question",{"text":112,"@type":113},"Gene expression and pretreatment biopsy clinical data from nine primary rectal tumor cohorts were integrated (N=826), and transcriptomic signatures were tested for pathologic complete response (pCR) while accounting for treatment regimen or CMS subtype.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signatures were linked to pCR and lack of pCR?",{"text":117,"@type":113},"Immune and stromal signatures were strongly associated with pCR and lack of pCR, respectively. The radiosensitivity signature (RSS) showed the strongest association.",{"name":119,"@type":110,"acceptedAnswer":120},"What role did oxaliplatin and radiosensitivity play in predicting response and outcomes?",{"text":121,"@type":113},"After adding oxaliplatin, stromal signatures switched direction and were associated with higher chances to achieve pCR. Survival associations were limited to pCR and RSS, and RSS in preoperative biopsies provided predictive information for neoadjuvant RT response specifically to 5FU.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343032,1790118531,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0502](https://doi.org/10.1158/2767-9764.CRC-23-0502)  OPEN ACCESS  \nStratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures  \nUmair Mahmood1, Andrew Blake1, Sanjay Rathee1, Leslie Samuel2, Graeme Murray2, David Sebag-Montefiore3, Simon Gollins4,5, Nicholas P. West3, Rubina Begum6, Simon P. Bach7, Susan D. Richman3, Phil Quirke3, Keara L. Redmond8, Manuel Salto-Tellez8, Viktor H. Koelzer9,10, Simon J. Leedham11, Ian Tomlinson1, Philip D. Dunne8, Francesca M. Buffa1,12, S:CORT consortium, Tim S. Maughan1,13, and Enric Domingo1,14  \n􀀶  \nABSTRACT  \nResponse to neoadjuvant radiotherapy (RT) in rectal cancer has been associated with immune and stromal features that are captured by transcriptional signatures. However, how such associations perform across different chemoradiotherapy regimens and within individual consensus molecular subtypes (CMS) and how they affect survival remain unclear. In this study, gene expression and clinical data of pretreatment biopsies from nine cohorts of primary rectal tumors were combined (N ¼ 826) . Exploratory analyses were done with transcriptomic signatures for the endpoint of pathologic complete response (pCR), considering treatment regimen or CMS subtype. Relevant findings were tested for overall survival and recurrence-free survival. Immune and stromal signatures were strongly associated with pCR and lack of pCR, respectively, in RT and capecitabine (Cap)/5-fluorouracil (5FU)– treated patients (N ¼ 387), in which the radiosensitivity signature (RSS) showed the strongest association. Upon addition of oxaliplatin (Ox; N ¼ 123), stromal signatures switched direction and showed higher chances to achieve pCR than without Ox (p for interaction 0.02) . Among Cap/  \n5FU patients, most signatures performed similarly across CMS subtypes, except cytotoxic lymphocytes that were associated with pCR in CMS1 and CMS4 cases compared with other CMS subtypes (p for interaction 0.04) . The only variables associated with survival were pCR and RSS. Although the frequency of pCR across different chemoradiation regimens is relatively similar, our data suggest that response rates may differ depending on the biological landscape of rectal cancer. Response toneoadjuvant RT in stroma-rich tumors may potentially be improved by the addition of Ox. RSS in preoperative biopsies provides predictive information for response specifically to neoadjuvant RT with 5FU.  \nSignificance: Rectal cancers with stromal features may respond better to RT and 5FU/Cap with the addition of Ox. Within patients not treated with Ox, high levels of cytotoxic lymphocytes associate with response only in immune and stromal tumors. Our analyses provide biological insights about the outcome by different radiotherapy regimens in rectal cancer.  \nIntroduction  \nColorectal cancer ranks the third most common tumor type in the Western world, with 30% of such cancers located in the rectum ( 1) . Currently, the  \n1Department of Oncology, Medical Science Division, University of Oxford, Oxford, United Kingdom. 2School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom. 3Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom. 4North Wales Cancer Treatment Centre, Besti Cadwaladr University Health Board, Bodelwyddan, United Kingdom. 5Lingen Davies Cancer Centre, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom. 6Cancer Research & University College London Clinical Trial Unit, London, United Kingdom. 7Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom. 8The Patrick G Johnston Centre for Cancer Research, Queens University Belfast, Belfast, United Kingdom. 9Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 10Department of Oncology and Nuffield Department of Medicine","cbCaickosCC5cXrI","https://ap.wps.com/l/cbCaickosCC5cXrI","pdf",3447560,12,"English","# Abstract\n# Introduction","[{\"question\":\"How were transcriptional signatures and clinical data combined in the study?\",\"answer\":\"Gene expression and pretreatment biopsy clinical data from nine primary rectal tumor cohorts were integrated (N=826), and transcriptomic signatures were tested for pathologic complete response (pCR) while accounting for treatment regimen or CMS subtype.\"},{\"question\":\"Which signatures were linked to pCR and lack of pCR?\",\"answer\":\"Immune and stromal signatures were strongly associated with pCR and lack of pCR, respectively. The radiosensitivity signature (RSS) showed the strongest association.\"},{\"question\":\"What role did oxaliplatin and radiosensitivity play in predicting response and outcomes?\",\"answer\":\"After adding oxaliplatin, stromal signatures switched direction and were associated with higher chances to achieve pCR. Survival associations were limited to pCR and RSS, and RSS in preoperative biopsies provided predictive information for neoadjuvant RT response specifically to 5FU.\"}]","Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures | PDF",1790049495,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d06412f82c211ed55e1e3a8cd0c0e750.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0f3219254d57b54479fe130c4ee467d.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a9bdaa072d1f7ea10048a5b60e560c0.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f93bd0152884c816cf8a486abeeff3db.webp",980,1259]